Altimmune Inc Registered Shs Stock , ALT

14.09 -0.60 -4.08%

Official Close 8/30/2021 NAS

Plus500. 72% of retail CFD accounts lose money

Loading..
Date Open Close Daily High Daily Low

Price change over selected period: 0% 0

Total Analysts: 9

Buy Ratings: 9 Neutral Ratings: 0 Sell Ratings: 0

Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}

Price *Price Target

Lowest: 25.00 Median: 40.67 Highest: 80.00

  • All
  • Buy
  • Hold
  • Sell
  2021 2022 2023 2024 2025
Revenue 2 4 119 257 495
Dividend - - - - -
Dividend Yield (in %) - - - - -
EPS -1.74 -1.81 -1.28 -0.93 -0.94
P/E Ratio -5.47 -5.25 -7.42 -10.23 -10.12
EBIT -71 -79 -99 -95 -132
EBITDA -59 -40 - - -
Net Profit -72 -78 -98 -95 -132
Net Profit Adjusted - - - - -
Pre-Tax Profit -70 -78 -98 -95 -132
Net Profit (Adjusted) - - - - -
EPS (Non-GAAP) ex. SOE -2.08 -2.01 - - -
EPS (GAAP) -1.59 -1.63 -1.00 1.13 1.37
Gross Income 2 7 103 227 707
Cash Flow from Investing 58 -1 0 0 -
Cash Flow from Operations -55 -29 -27 -28 -
Cash Flow from Financing 43 48 1 1 -
Cash Flow per Share - - - - -
Free Cash Flow -65 -34 20 38 -
Free Cash Flow per Share -1.66 -0.79 - - -
Book Value per Share - - - - -
Net Debt - - - - -
Research & Development Exp. 53 63 76 71 102
Capital Expenditure 16 1 0 0 -
Selling, General & Admin. Exp. 17 20 27 28 31
Shareholder’s Equity 205 268 - - -
Total Assets 223 286 - - -
  Previous Quarter
ending 06/30/21
Current Quarter
ending 09/30/21
Next Quarter
ending 12/31/21
Current Year
ending 12/31/21
Next Year
ending 12/31/22
Earnings Estimates
No. of Analysts 6 6 6 6 6
Average Estimate -0.505 USD -0.393 USD -0.430 USD -1.740 USD -1.812 USD
Year Ago -0.940 USD -0.540 USD -0.170 USD -1.910 USD -1.740 USD
Publish Date 8/10/2021 11/16/2021 3/31/2022 - -
Revenue Estimates
No. of Analysts 6 6 6 6 6
Average Estimate 2 USD 0 USD 0 USD 2 USD 4 USD
Year Ago 1 USD 3 USD 2 USD 8 USD 2 USD
Publish Date 8/10/2021 11/16/2021 3/31/2022 - -

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

*Price and Yield of the Respective Date

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The companys portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Risk

  • Low
  • Medium
  • High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Owner in %
Freefloat 85.49
State Street Corp. 9.28
VR Adviser LLC 8.81
Avoro Capital Advisor LLC 6.08
Velocity Pharmaceutical Holdings LLC 5.22
D. E. Shaw & Co. LP 5.03
RTW Investments LP 4.06
BlackRock Fund Advisors 3.97
Point72 Asset Management LP (Old) 3.94
Vanguard Group, Inc. (Subfiler) 3.91
Hudson Bay Capital Management LP 3.61
Credit Suisse Securities (USA) LLC (Broker) 3.60
Citadel LP 3.25
Renaissance Technologies LLC 3.11
CaaS Capital Management LP 2.89

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Say hello

Find us at the office

Chappa- Adamitis street no. 38, 81811 Tripoli, Libya

Give us a ring

Alda Runion
+69 213 130 910
Mon - Fri, 10:00-22:00

Say hello